The New York State Council of Health-system Pharmacists (NYSCHP) created a Grassroots Advocacy Committee in August 2018 to increase member engagement by facilitating local legislative visits.^[@CIT0001],[@CIT0002]^ The committee educates members on health-system pharmacy legislative priorities, helps members set up local meetings with their state legislators, and assists members in responding to legislators' questions. The coronavirus disease 2019 (COVID-19) pandemic created several barriers to our committee's efforts. These barriers included competing responsibilities of committee members, conflicting legislative priorities between the bills we had previously been advocating for and COVID-19--related bills, and difficulty in scheduling legislative visits given that the state legislature was largely conducting its business remotely. There was also an increase in executive orders by the governor of New York and state and federal healthcare-related legislation that affected pharmacists' scope of practice, requiring our review and response. This confluence of factors provided new opportunities for practice advancement and motivated new and existing members to participate in advocacy. We believe that increased advocacy efforts occurred, as some of the legislation drew national attention on social media and professional listservers. This article discusses how the COVID-19 pandemic shifted our organization's approach to advocacy, including changes to legislative visits and methods of communicating with members, coordinating with key stakeholders, and leveraging opportunities for optimizing pharmacists' scope of practice.

Legislative visits {#s1}
==================

Legislative visits are a staple of grassroots advocacy and one of the primary goals of our committee.^[@CIT0001],[@CIT0003]^ During the spring 2020 peak of the COVID-19 crisis, we were pensive about emphasizing legislative visits to avoid distracting members from their job responsibilities. However, because of the clear need for advocacy, including from members who remained interested in participating in advocacy activities, we shifted to encouraging the members to schedule virtual visits through conference calls and various online platforms. Members were able to choose from a number of free virtual platforms or defer to the legislator's preference on which platform to use. While the infrastructure for setting up and facilitating a legislative visit remained in place, some unique challenges required us to develop the following guidance for virtual visits.

1.  Premeeting preparation:

    1.  Reach out to legislator to schedule a visit (typically done by the constituent committee member).

    2.  Identify 1 or 2 individuals who have either attended a legislative visit or participated in a previsit informational session to lead the meeting and facilitate introductions.

    3.  Lead(s) should coordinate with the legislator's office on which technology will be used, including the specific online platform and who will be sending the invite (member vs legislator).

    4.  Test the platform with all committee participants before the meeting.

    5.  Lead(s) or constituent member who set up the visit should confirm the total number of participants planning to attend and send the invitation link only to that group; consider limiting the number of participants to less than 10 to minimize technological difficulties.

2.  During the meeting:

    1.  Join at least 15 minutes early so that technical issues can be addressed in advance and to ensure each participant is on time.

    2.  Lead(s) or the constituent member who sets up the visit should ask permission to take a picture or screenshot of the group for social media posting.

    3.  Lead(s) should solicit questions from the legislator.

As the pandemic evolves, organizations should provide crisis-specific talking points to members involved with grassroots advocacy. These talking points should contextualize how usual (ie, pre--COVID-19) legislative priorities remain relevant during the pandemic and address pharmacists' inclusion in new COVID-19--related legislation. We focused our talking points on how our proposed legislation would assist during the pandemic (eg, expansion of immunization authority for pharmacists). We were able to coordinate several virtual legislative visits successfully during the pandemic due to our ability to communicate our new priorities and process with our members.

Communication {#s2}
=============

Communication during a pandemic---especially a rapidly evolving one like the COVID-19 crisis---can be a significant challenge for organizations.^[@CIT0004]^ Initially, as a pandemic ramps up, pharmacists may become overwhelmed with changes in their facilities, including new clinical guidelines, redeployment of staff and equipment, new dispensing models, and a massive influx of critically ill patients. Pharmacists will require information about the rapidly changing regulatory landscape and interpretation of the new rules as local, state, or federal governments modify the scope of pharmacy practice. They may receive updates from their facility, health system, group purchasing organizations, and social media outlets. These sources do not always align and may have different interpretations and applications of the new laws; this results in an unmanageable amount of information that may be overly complex, not applicable to a pharmacist's profession or practice site, and difficult to digest. Therefore, during a pandemic, communication should:

1.  Be brief and relevant

2.  Occur at defined intervals (eg, daily, weekly)

3.  Support the individuals' professional duties

4.  Provide consistent messaging with clear explanations

5.  Identify a dedicated individual or team available for questions

6.  Demonstrate how the organization is supporting its members

7.  Identify issues that do not yet have a resolution and warrant further clarification

Our organization typically communicates via a monthly newsletter, posts on social media, and ad hoc broadcast emails; all originate from a variety of contributing individuals. During the early months of the CODIV-19 pandemic, we increased the frequency of NYSCHP email communications to provide brief, targeted updates on state executive orders and new regulatory actions and their impacts on pharmacy practice. Several issues remained unresolved or required clarification; when we were uncertain of the final resolution of an issue, we communicated this to avoid duplication of ongoing efforts (eg, by members reaching out for clarification on their own). We also conducted conference calls with NYSCHP local chapters to keep them informed of our efforts with the governor and the legislature and to coordinate with other key stakeholders (eg, the board of pharmacy, colleges and schools of pharmacy, state agencies, and other professional organizations).

We recommend identifying a key individual or team to address pandemic response communication. Having a specific point person helps funnel issues, questions, messaging, and follow-up through one individual, who can take back the information for further clarification within the organization's leadership. In addition, we recommend that organizations review social media feeds such as Facebook, Instagram, and Twitter to ensure relevance during a pandemic, as third parties may be responsible for uploading content to an organization's social media platforms. It may also be helpful to create a resource page with relevant information and a summary of all updates and the dates of those messages. Depending on the content of the messages, this resource page can be made public or accessible only to members via a log-in portal.

Coordination by key stakeholders {#s3}
================================

Pharmacy and health-system organizations help shape legislation, regulations, and executive actions; their involvement in advocacy is more acutely necessary during a pandemic.^[@CIT0005]^ Because these organizations represent different constituencies within the world of pharmacy, they may have vastly different priorities. We recommend regular communication and coordination among the key stakeholders. In New York we have a quarterly "pharmacy conference" in which major professional organizations, colleges and schools of pharmacy, and state agencies report on important issues. During the early months of the COVID-19 pandemic, the conference was reconfigured into a weekly teleconference call that allowed us to respond rapidly to policy changes, coordinate a single message, and identify a responsible individual or organization as the lead for each task.

In one example, the governor issued an executive order regarding hydroxychloroquine as COVID-19 ramped up in New York. The order stated, "No pharmacist shall dispense hydroxychloroquine or chloroquine except when written as prescribed for an FDA \[Food and Drug Administration\]-approved indication." ^[@CIT0006]^ It was not clear which practice area(s) this order pertained to; therefore, institutional pharmacists providing care to patients with COVID-19 were concerned that they were violating the order. NYSCHP communicated with the other pharmacy organizations requested clarification of the directive's scope from the board of pharmacy, which was unable to provide clarification. Therefore, we voiced our concerns by contacting the governor's team directly. Shortly thereafter, the governor issued a new executive order with updated language clarifying that the order applied only to outpatient prescriptions. During this time, many other executive orders and legislative changes required clarification and updates prior to statewide implementation. Unfortunately, despite coordination with other organizations and clarification from state agencies and the governor's office, many issues remained unresolved as of the time of writing. Additional examples of COVID-19--related legislative issues and actions taken to obtain clarification are listed in [Table 1](#T1){ref-type="table"}.

###### 

Examples of COVID-19--Related Legislative Issues

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Issue                                                                                                                                                                                                                                                                                           Committee Members Communicated With:                                                                           Committee Actions                                                                                                                                                                                                                                                                                                                                                                                     Outcome/Comments
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  *Part III licensing examination* ^a^\                                                                                                                                                                                                                                                           Other pharmacy organizations, colleges and schools of pharmacy                                                 Letter of support: Committee members coordinated to draft a letter to the governor's office that provided 3 recommendations for consideration: (1) a waiver of Part III for 2020 graduates, (2) provisional licensure subject to completion of Part III at a later date, and (3) empowering colleges and schools of pharmacy to document competency in collaboration with NYS Education Department.   The examination was eventually rescheduled, and the testing process was changed to a computer-based exam that candidates could take from home.
  Compounding examination was indefinitely postponed; new pharmacy graduates and some licensed pharmacists transferring from other states were unable to get licensed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  *Out-of-state pharmacists*\                                                                                                                                                                                                                                                                     BOP                                                                                                            Communication with state agencies: Committee sought clarification from the executive secretary of the BOP, who clarified that the NYS Education Department interpreted the rule as not applying to pharmacists licensed in other states.                                                                                                                                                              Pharmacists with NYS licensure but inactive registration were mostly retired pharmacists.
  Executive order allowed licensed pharmacists to practice in NYS despite their registration not being currently active with BOP; clarification regarding pharmacists licensed in other states was needed.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  *Pharmacist involvement in testing for COVID-19*\                                                                                                                                                                                                                                               Governor's office, NYS Department of Health, NYS Education Department, other ASHP-affiliated state societies   Communication with state agencies: NYSCHP sought clarification from NYS Education Department, which clarified that the scope of practice was not within the pharmacist's authority until the NYS Department of Health posted training (that occurred several weeks after the governor released the executive order).                                                                                  NYSCHP communicated the clarification to our members to prevent them from initiating testing protocols prior to meeting the executive order requirements.
  Executive order allowed pharmacists to order and administer tests for COVID-19 after completion of training by the NYS Department of Health; as training had not yet been developed at the time the executive order was released, it was unclear if pharmacists could participate in testing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  *Student Loan Forgiveness for Frontline Healthcare Workers Act (HR 6720)*\                                                                                                                                                                                                                      ASHP, legislator (sponsoring congresswoman from NYS)                                                           Communication with sponsoring legislator: NYSCHP shared concerns with ASHP after major social media publicity (due to lack of pharmacists' specific inclusion in HR 6720). ASHP sent a letter to the legislator.                                                                                                                                                                                      NYSCHP shared the ASHP letter with its members and asked them to contact their members of Congress.
  Pharmacists were not explicitly mentioned as healthcare professionals in the bill.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BOP, board of pharmacy; COVID-19, coronavirus disease 2019; NYS, New York State; NYSCHP, New York State Council of Health-system Pharmacists.

^a^Part III of the pharmacist licensing examination series (Prescription Compounding and Pharmacy Practice).

Leveraging legislative opportunities during the COVID-19 crisis {#s4}
===============================================================

As the COVID-19 crisis progressed, we started to see an increase in executive orders by the governor as well as state and federal COVID-19--related bills. This legislation often included practice changes that optimized pharmacists' scope of practice that might not have occurred outside of a pandemic. Therefore, although our previous bills were temporarily on hold, new legislation provided opportunity for our profession. There was a significant amount of media attention on COVID-19--related legislation, including social media campaigns that referenced pharmacists' inclusion (or, in some cases, omission). Additionally, shifting legislative priorities have given new opportunities for pharmacists to be involved in and reimbursed for telehealth in the ambulatory care setting. This development energized and mobilized our membership to ask questions and seek out opportunities for advocacy. It also allowed our organization to be more strategic and assess how pharmacists could be incorporated into legislation, examine opportunities within legislation for practice advancement, ensure that pharmacies and pharmacists were included in potential budget considerations for COVID-19--related funding, and push forward new legislation that otherwise might not have had the momentum to move forward.

For example, the need for increased testing for COVID-19 led to the inclusion of pharmacists as qualified healthcare professionals to be able to order and administer such tests (an NYSCHP message to members regarding this issue is shown in [eAppendix A](#sup1){ref-type="supplementary-material"}).^[@CIT0006]^ The ability to order and administer tests like this had been a legislative priority for pharmacy organizations in New York for many years. Further, approval of a future COVID-19 vaccine will increase the need for immunizers. The legislature introduced a bill allowing pharmacists to administer such a hypothetical vaccine, and it passed within one week.^[@CIT0007]^ Approval of this bill marked the first time a vaccine was "preapproved" for administration by pharmacists and stands in contrast to several FDA-approved and Centers for Disease Control and Prevention--recommended vaccines that cannot be administered by pharmacists in New York (an NYSCHP message to members regarding this issue is shown in [eAppendix B](#sup1){ref-type="supplementary-material"}).^[@CIT0008]^

The environment of a pandemic can also be one of opportunity and growth. As Winston Churchill is reported to have said, "Never let a good crisis go to waste." Indeed, crises in healthcare may require rapid change, increased resources, heightened collaboration with key stakeholders, and enhanced leadership to ensure public safety. Public policy changes, which typically take years, may require execution in weeks or even days to ensure healthcare professionals have the right tools to take care of patients. These rapid changes can occur when organizations can navigate through disruption and effectively engage in advocacy.

Conclusion {#s5}
==========

Advocacy is critical to the growth of the pharmacy profession and has been of utmost importance during the COVID-19 pandemic. Although competing responsibilities will challenge advocacy efforts, pharmacists can maintain their advocacy presence during a pandemic by shifting their approach to virtual legislative visits, integrating pharmacy within new legislation, and coordinating efforts amongst different organizations and government agencies. In a rapidly changing legislative environment, flexibility, effective communication, and sustained involvement are essential. Altogether these strategies can allow for implementation of innovative practice changes that improve pharmacists' ability to manage patient care both during and after the pandemic.

Supplementary Material
======================

###### 

Click here for additional data file.

*The* Frontline Pharmacist *column gives staff pharmacists an opportunity to share their experiences and pertinent lessons related to day-to-day practice. Topics include workplace innovations, cooperating with peers, communicating with other professionals, dealing with management, handling technical issues related to pharmacy practice, and supervising technicians. Readers are invited to submit manuscripts, ideas, and comments to* AJHP *at [ajhp\@ashp.org](https://ajhp@ashp.org)*.
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